Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT

The Suppression of Ovarian Function Trial (SOFT) randomized premenopausal women with HR-positive breast cancer to 5 years of adjuvant tamoxifen, 5 years of adjuvant tamoxifen plus ovarian function suppression (OFS), or 5 years of adjuvant exemestane plus OFS. After a median follow-up of 12 years, there remained a benefit from including OFS in adjuvant endocrine therapy, with an absolute improvement in OS more apparent with higher baseline risk of recurrence.